- Company
- Market for montelukast revive…overcomes impurity issue
- by Kim, Jin-Gu Nov 14, 2023 05:49am
- The market for asthma treatments containing the ingredient montelukast has succeeded in complete revival. This market shrank significantly in 2020-2021 due to the side effects issue and the COVID-19 outbreak, but made a rebound last year, and is expected to expand to the largest size ever this year. The market which remained stagnant fo
- Company
- Conquest of low survival gallbladder cancer
- by Nov 14, 2023 05:49am
- In the area of bile duct cancer, where survival rates are low and treatment options are scarce, new drug candidates from domestic pharmaceutical companies have been confirmed in clinical practice and are one step closer to commercialization. HDB001A, a new drug candidate for gallbladder cancer that Handok is developing, has recently been approve
- Company
- Novartis loses 2nd trial for its Entresto patent
- by Kim, Jin-Gu Nov 13, 2023 05:23am
- The second trial over Novartis’s heart failure treatment ‘Entresto (valsartan+ sacubitril) again ended with the victory of the Korean generic companies. If the companies succeed in winning the remaining 2 suits, the companies will be one step closer to the early release of their generics. Generic companies win first and second tr
- Company
- Amvuttra receives orphan drug designation
- by Eo, Yun-Ho Nov 13, 2023 05:23am
- ‘Amvuttra,’ the first new drug for amyloidosis with polyneuropathy to be introduced since ‘Vyndaqel,’ has been designated an orphan drug in Korea. The Ministry of Food and Drug Safety announced so through a recent notice of orphan drug designation. siRNA therapy Amvuttra (Vutrisiran) is administered subcutaneously at once every thr
- Company
- NMOSD drug Enspryng likely to be reimbursed in December
- by Eo, Yun-Ho Nov 13, 2023 05:23am
- ‘Enspryng’ a new drug for neuromyelitis optica spectrum disorder (NMOSD), is expected to be listed for reimbursement in Korea within the year. According to industry sources, Roche Korea completed drug pricing negotiations with the National Health Insurance Service for the reimbursement of its NMOSD treatment Ensprying (satralizumab). Th
- Company
- Korea Pharma applies for approval of its 24hr ADHD drug
- by Lee, Seok-Jun Nov 10, 2023 05:19am
- Korea Pharma announced on the 9th that it had applied for marketing authorization for its 24-hour long-acting ADHD treatment ‘Methydur SR Cap.’ Methydur is a treatment for attention deficit hyperactivity disorder (ADHD) in children and adolescents developed by Orient Pharmaceuticals in Taiwan. The main substance contained in Methydur i
- Company
- Development active for microbiome-based therapies in Korea
- by Nho, Byung Chul Nov 10, 2023 05:19am
- Microbiome-based therapies have been expanding their therapeutic areas from simple digestives to immunology and oncology, receiving industry attention. Based on research results that showed that imbalances in the human microbiome are highly correlated with various incurable diseases, such as cancer and obesity, and can cause immune and me
- Company
- Will Lixiana hit the 100 billion won mark for the NOAC RX?
- by Kim, Jin-Gu Nov 10, 2023 05:19am
- Attention is focused on whether Daiichi Sanko Lixiana will become the first NOAC drug to exceed 100 billion won in annual prescription sales. As of the third quarter, the cumulative prescription amount was 78.2 billion won, and if this trend continues, it is expected that prescriptions will easily exceed 100 billion won by the end of the year
- Company
- Will Trodelbi become a second-line standard tx
- by Nov 9, 2023 05:43am
- Antibody Drug Conjugate (ADC) anticancer drugs first appeared in the domestic triple-negative breast cancer treatment market. To date, there have been no treatment options targeting triple-negative breast cancer treatment other than immunotherapy drugs and PARP inhibitors. Gilead is aiming to make Trodelbi the standard treatment option in t
- Company
- Prescriptions of HCV market leader Mavyret halves in 1 yr
- by Kim, Jin-Gu Nov 9, 2023 05:43am
- Outpatient prescription performance of ‘Mavyret,’ the No. 1 product in the hepatitis C treatment market, has shrunk to less than half in just 1 year. In addition to the decrease in overall market size due to the decline in hepatitis C patients, Mavyret’s newly released competitors 'Epclusa' and ‘Vosevi’ have been rapidly expanding th
